Table 4.
Clinical Outcomes With Genotype‐guided Therapy or Conventional Therapy in Patients With High and Low ABCD‐GENE‐Score and Carriers of CYP2C19 Loss‐of‐Function Mutation
| Variable |
High (≥10) ABCD‐GENE scores (n=856) |
Low (<10) ABCD‐GENE score (n=839) |
Pint | ||||
|---|---|---|---|---|---|---|---|
| GGT | CT | HR (95% CI) | GGT | CT | HR (95% CI) | ||
| Time to first event analysis | |||||||
| All‐cause death, MI, or stroke | 3.2% | 4.1% | 0.76 (0.37–1.57) | 1.5% | 1.9% | 0.81 (0.28–2.32) | 0.93 |
| Cardiovascular death, MI, stroke, definite or probable ST, or severe recurrent ischemia | 5.4% | 7.2% | 0.73 (0.42–1.26) | 3.1% | 4.7% | 0.64 (0.31–1.31) | 0.78 |
| All‐cause death | 1.0% | 1.4% | 0.67 (0.19–2.36) | 0.5% | 1.0% | 0.54 (0.10–2.94) | 0.84 |
| Major/minor bleeding | 1.3% | 1.7% | 0.72 (0.23–2.25) | 2.3% | 1.2% | 1.95 (0.65–5.82) | 0.21 |
Estimates are calculated by the Kaplan‒Meier method.
ABCD‐GENE indicates Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping; CT, conventional therapy; GGT, genotype‐guided therapy; HR, hazard ratio; MI, myocardial infarction; and ST, stent thrombosis.